Literature DB >> 19054893

The global burden of urinary bladder cancer.

D Maxwell Parkin1.   

Abstract

Statistics on the incidence of bladder cancer are particularly hard to interpret, because of changing classification, variations in counting of multiple cancers in the same individual and, most importantly, the variable inclusion of non-invasive cancers in different data sets. Mortality statistics are almost certainly more comparable, but as indirect estimators of disease risk, require some cautious interpretation, because of differing survival between populations, and over time. Cancer of the bladder is estimated to be the ninth most common cause of cancer worldwide (357 000 cases in 2002) and the 13th most numerous cause of death from cancer (145 000 deaths). Rates in males are three to four times those in females. Incidence rates are high in many southern and eastern European countries, in parts of Africa and the Middle East, and in North America. The highest estimated mortality is in Egypt, where rates are more than three times greater than the highest rates in Europe and eight times those in the USA. In the USA, the incidence in whites is higher than in blacks. In general, in Western countries, incidence rates have been rising, but the increase has slowed or stopped in many. Mortality rates are, for the most part, decreasing. Trends are more variable in developing countries. To some extent, the geography and time trends are related to prevalence of known risk factors, especially exposure to tobacco (responsible for almost one-third of bladder cancer deaths) and, in some specific areas, schistosomiasis.

Entities:  

Mesh:

Year:  2008        PMID: 19054893     DOI: 10.1080/03008880802285032

Source DB:  PubMed          Journal:  Scand J Urol Nephrol Suppl        ISSN: 0300-8886


  109 in total

1.  Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.

Authors:  Ying-Li Lin; Xiao-Qiang Liu; Wen-Ping Li; Guang Sun; Chun-Ting Zhang
Journal:  Int Urol Nephrol       Date:  2011-04-24       Impact factor: 2.370

2.  Reexamination of total fluid intake and bladder cancer in the Health Professionals Follow-up Study Cohort.

Authors:  Jiachen Zhou; Scott Smith; Edward Giovannucci; Dominique S Michaud
Journal:  Am J Epidemiol       Date:  2012-02-21       Impact factor: 4.897

3.  Surgical oncology. Alternatives to surgery after failure of instillation therapy.

Authors:  Christian Weiss; Claus Rödel
Journal:  Nat Rev Clin Oncol       Date:  2010-06       Impact factor: 66.675

4.  The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis.

Authors:  Yu Yang; Chao Luo; R Feng; Sheng Bi
Journal:  J Cancer Res Clin Oncol       Date:  2010-11-24       Impact factor: 4.553

5.  Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model.

Authors:  Cheng-Huang Shen; Jia-Jen Shee; Jin-Yi Wu; Yi-Wen Lin; Jiann-Der Wu; Yi-Wen Liu
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

6.  Implications of LINE1 methylation for bladder cancer risk in women.

Authors:  Charlotte S Wilhelm; Karl T Kelsey; Rondi Butler; Silvia Plaza; Luc Gagne; M Scot Zens; Angeline S Andrew; Steven Morris; Heather H Nelson; Alan R Schned; Margaret R Karagas; Carmen J Marsit
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

7.  Serum vitamin D and risk of bladder cancer.

Authors:  Alison M Mondul; Stephanie J Weinstein; Satu Männistö; Kirk Snyder; Ronald L Horst; Jarmo Virtamo; Demetrius Albanes
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

8.  A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.

Authors:  Mohamed S Zaghloul; Rimoun Boutrus; Hisham El-Hossieny; Yasser Abdel Kader; Inas El-Attar; Mohamed Nazmy
Journal:  Int J Clin Oncol       Date:  2010-04-01       Impact factor: 3.402

9.  Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.

Authors:  Julia Fazel; Silvia Rötzer; Christof Seidl; Benedikt Feuerecker; Michael Autenrieth; Gregor Weirich; Frank Bruchertseifer; Alfred Morgenstern; Reingard Senekowitsch-Schmidtke
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

10.  Bioinformatics analysis of the target gene of fibroblast growth factor receptor 3 in bladder cancer and associated molecular mechanisms.

Authors:  Xing Ai; Zhuo-Min Jia; Juan Wang; Gui-Ping DI; X U Zhang; Fengling Sun; Tong Zang; Xiumei Liao
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.